Cargando…
Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients
COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309986/ https://www.ncbi.nlm.nih.gov/pubmed/34358130 http://dx.doi.org/10.3390/vaccines9070714 |
_version_ | 1783728652202016768 |
---|---|
author | Amodio, Emanuele Capra, Giuseppina Casuccio, Alessandra Grazia, Simona De Genovese, Dario Pizzo, Stefano Calamusa, Giuseppe Ferraro, Donatella Giammanco, Giovanni Maurizio Vitale, Francesco Bonura, Floriana |
author_facet | Amodio, Emanuele Capra, Giuseppina Casuccio, Alessandra Grazia, Simona De Genovese, Dario Pizzo, Stefano Calamusa, Giuseppe Ferraro, Donatella Giammanco, Giovanni Maurizio Vitale, Francesco Bonura, Floriana |
author_sort | Amodio, Emanuele |
collection | PubMed |
description | COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations > 200 AU/mL. In a Tobit multivariable regression analysis, SARS-CoV-2 vaccination was statistically significantly associated with increased IgG concentrations (β coef = 266.4; p < 0.001). A statistically significant reduction in SARS-CoV-2 IgG concentrations was found with older age (β coef = −1.96 per year increase; p < 0.001), male sex (β coef = −22.3; p < 0.001), and days after immunization (β coef = −1.67 per day increase; p < 0.001). Our findings could support the vaccination campaigns confirming the high immunogenicity of the SARS-CoV-2 vaccine under investigation with respect to the natural infection. Further studies will be required for evaluating the role of age and days after immunization in the persistence of vaccine antibodies and protection from the disease. |
format | Online Article Text |
id | pubmed-8309986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83099862021-07-25 Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients Amodio, Emanuele Capra, Giuseppina Casuccio, Alessandra Grazia, Simona De Genovese, Dario Pizzo, Stefano Calamusa, Giuseppe Ferraro, Donatella Giammanco, Giovanni Maurizio Vitale, Francesco Bonura, Floriana Vaccines (Basel) Article COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations > 200 AU/mL. In a Tobit multivariable regression analysis, SARS-CoV-2 vaccination was statistically significantly associated with increased IgG concentrations (β coef = 266.4; p < 0.001). A statistically significant reduction in SARS-CoV-2 IgG concentrations was found with older age (β coef = −1.96 per year increase; p < 0.001), male sex (β coef = −22.3; p < 0.001), and days after immunization (β coef = −1.67 per day increase; p < 0.001). Our findings could support the vaccination campaigns confirming the high immunogenicity of the SARS-CoV-2 vaccine under investigation with respect to the natural infection. Further studies will be required for evaluating the role of age and days after immunization in the persistence of vaccine antibodies and protection from the disease. MDPI 2021-07-01 /pmc/articles/PMC8309986/ /pubmed/34358130 http://dx.doi.org/10.3390/vaccines9070714 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Amodio, Emanuele Capra, Giuseppina Casuccio, Alessandra Grazia, Simona De Genovese, Dario Pizzo, Stefano Calamusa, Giuseppe Ferraro, Donatella Giammanco, Giovanni Maurizio Vitale, Francesco Bonura, Floriana Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title | Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title_full | Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title_fullStr | Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title_full_unstemmed | Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title_short | Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients |
title_sort | antibodies responses to sars-cov-2 in a large cohort of vaccinated subjects and seropositive patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309986/ https://www.ncbi.nlm.nih.gov/pubmed/34358130 http://dx.doi.org/10.3390/vaccines9070714 |
work_keys_str_mv | AT amodioemanuele antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT capragiuseppina antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT casuccioalessandra antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT graziasimonade antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT genovesedario antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT pizzostefano antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT calamusagiuseppe antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT ferrarodonatella antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT giammancogiovannimaurizio antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT vitalefrancesco antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients AT bonurafloriana antibodiesresponsestosarscov2inalargecohortofvaccinatedsubjectsandseropositivepatients |